Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signalingJingyue Yao, Libin Wei|Acta Pharmacologica Sinica|2021Cited by 51